$125,000 of COHERUS BIOSCIENCES INC. lobbying was just disclosed, from Q3 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues related to oncology, Medicare coverage, domestic production of essential drugs, supply chain security, PILLS Act, Biosecure Act, Loans and grants for biologic production Issues related to drug development, oncology, IRA implementation, supply chain security, BIOSECURE as a policy matter, PILLS Act, and domestic production of essential drugs. Strategic National Stockpile of acute radiation syndrome medical counter measures. Administration for Strategic Preparedness & Response."
You can find more data on corporate lobbying on Quiver Quantitative.
CHRS Insider Trading Activity
CHRS insiders have traded $CHRS stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $CHRS stock by insiders over the last 6 months:
- MATS WAHLSTROM sold 99,988 shares for an estimated $73,881
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
CHRS Hedge Fund Activity
We have seen 47 institutional investors add shares of CHRS stock to their portfolio, and 66 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- POINT72 ASSET MANAGEMENT, L.P. removed 5,283,292 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $4,263,616
- RUBRIC CAPITAL MANAGEMENT LP removed 4,390,954 shares (-83.5%) from their portfolio in Q2 2025, for an estimated $3,211,104
- MILLENNIUM MANAGEMENT LLC removed 1,517,799 shares (-52.3%) from their portfolio in Q2 2025, for an estimated $1,109,966
- PANAGORA ASSET MANAGEMENT INC added 794,329 shares (+inf%) to their portfolio in Q2 2025, for an estimated $580,892
- LOS ANGELES CAPITAL MANAGEMENT LLC removed 603,597 shares (-60.9%) from their portfolio in Q2 2025, for an estimated $441,410
- VANGUARD GROUP INC removed 581,390 shares (-5.2%) from their portfolio in Q2 2025, for an estimated $425,170
- DISCIPLINED GROWTH INVESTORS INC /MN removed 566,746 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $457,364
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
CHRS Analyst Ratings
Wall Street analysts have issued reports on $CHRS in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 04/29/2025
To track analyst ratings and price targets for CHRS, check out Quiver Quantitative's $CHRS forecast page.
CHRS Price Targets
Multiple analysts have issued price targets for $CHRS recently. We have seen 2 analysts offer price targets for $CHRS in the last 6 months, with a median target of $4.025.
Here are some recent targets:
- Douglas Tsao from HC Wainwright & Co. set a target price of $7.0 on 04/29/2025
- Ashwani Verma from UBS set a target price of $1.05 on 04/24/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
